New combo attack on lymphoma shows promise in early trial
NCT ID NCT03035331
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the safest dose and see if the combination could shrink tumors. Only 11 people took part, so the results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dendritic cell therapy, pembrolizumab (Keytruda), and cryoablation
What this could lead to
If it works, this combination could offer a new treatment option for patients with non-Hodgkin lymphoma that has come back after other therapies.
What could go wrong
This was a very small, early-phase trial with only 11 participants, so results may not apply to everyone. The combination also carries risks of serious side effects like immune reactions and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States